Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Möllgård L, Lehman S, Xu D, Covelli A, Gustavsson B, Paul C. Tidefelt U, et al. Among authors: juliusson g. J Clin Oncol. 2000 May;18(9):1837-44. doi: 10.1200/JCO.2000.18.9.1837. J Clin Oncol. 2000. PMID: 10784624 Clinical Trial.
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Karlsson K, Strömberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A, Kimby E, Lärfars G, Cristiansen I, Nilsson G, Celsing F, Sundström G, Luthman M, Tidefelt U, Wallvik J, Juliusson G. Karlsson K, et al. Among authors: juliusson g. Br J Haematol. 2002 Mar;116(3):538-48. doi: 10.1046/j.0007-1048.2001.03296.x. Br J Haematol. 2002. PMID: 11849209 Free article. Clinical Trial.
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: juliusson g. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.
Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.
Tobin G, Thunberg U, Johnson A, Eriksson I, Söderberg O, Karlsson K, Merup M, Juliusson G, Vilpo J, Enblad G, Sundström C, Roos G, Rosenquist R. Tobin G, et al. Among authors: juliusson g. Blood. 2003 Jun 15;101(12):4952-7. doi: 10.1182/blood-2002-11-3485. Epub 2003 Feb 13. Blood. 2003. PMID: 12586612 Free article.
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Juliusson G, Höglund M, Karlsson K, Löfgren C, Möllgård L, Paul C, Tidefelt U, Björkholm M; Leukemia Group of Middle Sweden. Juliusson G, et al. Br J Haematol. 2003 Dec;123(5):810-8. doi: 10.1046/j.1365-2141.2003.04702.x. Br J Haematol. 2003. PMID: 14632771 Free article. Clinical Trial.
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
Castor A, Nilsson L, Astrand-Grundström I, Buitenhuis M, Ramirez C, Anderson K, Strömbeck B, Garwicz S, Békássy AN, Schmiegelow K, Lausen B, Hokland P, Lehmann S, Juliusson G, Johansson B, Jacobsen SE. Castor A, et al. Among authors: juliusson g. Nat Med. 2005 Jun;11(6):630-7. doi: 10.1038/nm1253. Epub 2005 May 22. Nat Med. 2005. PMID: 15908956
292 results